Show simple item record

dc.contributor.authorGrassadonia, Antonino
dc.contributor.authorGraziano, Vincenzo
dc.contributor.authorIezzi, Laura
dc.contributor.authorVici, Patrizia
dc.contributor.authorBarba, Maddalena
dc.contributor.authorPizzuti, Laura
dc.contributor.authorCicero, Giuseppe
dc.contributor.authorKrasniqi, Eriseld
dc.contributor.authorMazzotta, Marco
dc.contributor.authorMarinelli, Daniele
dc.contributor.authorAmodio, Antonella
dc.contributor.authorNatoli, Clara
dc.contributor.authorTinari, Nicola
dc.date.accessioned2021-07-07T14:01:05Z
dc.date.available2021-07-07T14:01:05Z
dc.date.issued2021-07-03
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/324866
dc.description.abstractThe neutrophil to lymphocyte ratio (NLR) is a promising predictive and prognostic factor in breast cancer. We investigated its ability to predict disease-free survival (DFS) and overall survival (OS) in patients with luminal A- or luminal B-HER2-negative breast cancer who received neoadjuvant chemotherapy (NACT). Pre-treatment complete blood cell counts from 168 consecutive patients with luminal breast cancer were evaluated to assess NLR. The study population was stratified into NLRlow or NLRhigh according to a cut-off value established by receiving operator curve (ROC) analysis. Data on additional pre- and post-treatment clinical-pathological characteristics were also collected. Kaplan–Meier curves, log-rank tests, and Cox proportional hazards models were used for statistical analyses. Patients with pre-treatment NLRlow showed a significantly shorter DFS (HR: 6.97, 95% CI: 1.65–10.55, p = 0.002) and OS (HR: 7.79, 95% CI: 1.25–15.07, p = 0.021) compared to those with NLRhigh. Non-ductal histology, luminal B subtype, and post-treatment Ki67 ≥ 14% were also associated with worse DFS (p = 0.016, p = 0.002, and p = 0.001, respectively). In a multivariate analysis, luminal B subtype, post-treatment Ki67 ≥ 14%, and NLRlow remained independent prognostic factors for DFS, while only post-treatment Ki67 ≥ 14% and NLRlow affected OS. The present study provides evidence that pre-treatment NLRlow helps identify women at higher risk of recurrence and death among patients affected by luminal breast cancer treated with NACT.
dc.languageen
dc.publisherMDPI
dc.subjectluminal breast cancer
dc.subjectneoadjuvant chemotherapy
dc.subjectneutrophil to lymphocyte ratio (NLR)
dc.subjectpredictive/prognostic biomarkers
dc.titlePrognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting
dc.typeArticle
dc.date.updated2021-07-07T14:01:05Z
prism.issueIdentifier7
prism.publicationNameCells
prism.volume10
dc.identifier.doi10.17863/CAM.72320
dcterms.dateAccepted2021-06-28
rioxxterms.versionofrecord10.3390/cells10071685
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidGraziano, Vincenzo [0000-0001-7656-824X]
dc.identifier.eissn2073-4409


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record